Medicago-GSK COVID-19 vaccine candidate to enter large human studies

Nov 12 (Reuters) - A combination of an experimental COVID-19 vaccine from Canadian drug developer Medicago and Britain’s GSK , will enter into large human studies involving more than 30,000 healthy adults, the two companies said on Thursday.

The news comes days after the companies said the vaccine candidate produced virus-neutralizing antibodies in all volunteers in an early-stage study. (Reporting by Pushkala Aripaka in Bengaluru; Editing by Shinjini Ganguli)


Reuters Breakingviews is the world's leading source of agenda-setting financial insight. As the Reuters brand for financial commentary, we dissect the big business and economic stories as they break around the world every day. A global team of about 30 correspondents in New York, London, Hong Kong and other major cities provides expert analysis in real time.

Sign up for a free trial of our full service at and follow us on Twitter @Breakingviews and at All opinions expressed are those of the authors.